Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 265 clinical trials
  • None views
  • None views
  • None views
  • None views
  • None views
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical study in adult patients with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable …

RAD51D
prostate cancer
psa level
liver metastasis
rucaparib
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.

  • 0 views
  • 13 May, 2025
  • 3 locations
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

adenocarcinoma of prostate
lymphadenopathy
metastasis
prostate cancer
abiraterone
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

metastasis
metastatic castration-resistant prostate cancer
diphosphonates
progressive disease
bone lesion
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

platelet transfusion
metastasis
abiraterone
gonadotropin releasing hormone
antiandrogen therapy
  • 0 views
  • 19 Feb, 2024
  • 4 locations